Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Identifier:
D9289C00008
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
Date
Oct 2024 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
Date
Oct 2024 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.

Trial Locations

Location
Status
Location
Research Site
Beijing, China, CN-100730
Status
N/A
Location
Research Site
Guangzhou, China, 510100
Status
N/A
Location
Research Site
Hangzhou, China, 310003
Status
N/A
Location
Research Site
Nantong, China, 226001
Status
N/A
Location
Research Site
Shanghai, China, 200040
Status
N/A
Location
Research Site
Tianjin, China, 300020
Status
N/A